What it is
Cerebrolysin is not a single peptide. It is a standardized preparation made by controlled enzymatic breakdown of purified pig brain protein, yielding a mixture of low-molecular-weight peptides plus free amino acids. Where marketed, it is given by intravenous infusion or intramuscular injection in defined courses.
The proposed mechanism is described as “neurotrophic-like.” Laboratory work suggests the peptide fraction partially mimics the body’s own neurotrophic factors — proteins such as BDNF, GDNF and CNTF that support neuron survival, synapse formation and repair. In animal models of stroke and head injury it has been reported to reduce excitotoxic damage and support neuroplasticity.
That is the theory. What human trials have shown is more complicated.
What the research shows
Acute ischemic stroke — the largest evidence base, and it conflicts.
The 2020 Cochrane systematic review pooled seven randomized trials in 1,773 people with acute ischemic stroke. Its moderate-certainty conclusion: adding Cerebrolysin to standard therapy probably does not reduce death from any cause, probably makes little or no difference to total serious adverse events, and probably increases non-fatal serious adverse events. The reviewers noted the manufacturer supported three of the multicenter studies.
A 2025 systematic review and meta-analysis pooled 14 randomized trials and 2,884 patients and reached a partly different conclusion: a modest but statistically significant improvement in early neurological scores (NIHSS mean difference 1.39 points, 95% CI 0.53–2.25), with substantial heterogeneity between trials. The outcome that matters most to patients — functional independence at follow-up — was not significantly improved (RR 1.31, 95% CI 0.90–1.91). The authors concluded the drug “may offer benefits for early neurological recovery” while “evidence for functional independence remains inconclusive.”
Two rigorous syntheses of overlapping data disagreeing on direction of effect is itself a finding. It tells you the underlying trials are not decisive.
Traumatic brain injury — small and industry-funded. The CAPTAIN prospective meta-analysis combined two randomized, placebo-controlled trials in moderate-to-severe TBI, total enrollment 185 patients. It reported a small-to-medium effect on a composite of functional and neuropsychological scales at day 30 and day 90 (standardized mean difference 0.31 and 0.34). One trial was funded by an unrestricted manufacturer grant. That is a preliminary signal, not an established treatment effect.
Vascular dementia — very low quality evidence. The 2019 Cochrane review included six trials and 597 participants from China, Russia and Romania. Where funding was disclosed, all were industry-supported. Benefits were reported for cognition and global function, but both were graded very low-quality evidence, with high risk of bias and significant heterogeneity. The reviewers concluded that if benefits exist, “the effects may be too small to be clinically meaningful.”
The pattern is worth naming: most of this evidence comes from outside the United States, much of it was manufacturer-supported, and the most independent appraisals are the least enthusiastic.
Who may be a candidate
The people who ask us about Cerebrolysin are typically:
- Adults recovering from a documented brain injury who have plateaued on conventional rehabilitation
- Patients with vascular risk factors and subjective cognitive complaints seeking a broader workup
- Patients who encountered it abroad and want a physician’s honest read on the evidence
- Adults who want a structured assessment of brain health, not a single intervention
For this compound, the limiting factor in the United States is not candidacy. It is legal availability.
What treatment looks like here
Plainly: Cerebrolysin is not FDA-approved and is not lawfully available through United States pharmaceutical channels. Dr. St. Marie will discuss the evidence, the regulatory position and what is realistically available to you before any plan is made. A consultation about Cerebrolysin involves:
Comprehensive evaluation. A full history — injury or vascular events, medications, sleep, metabolic and cardiovascular status, mood, and your specific cognitive complaints.
Laboratory work. Typically metabolic and inflammatory markers, lipids and lipoprotein subfractions, homocysteine, A1c and fasting insulin, thyroid, B12, folate, vitamin D, iron studies and hormone evaluation. Cognitive symptoms are downstream of vascular, metabolic and sleep physiology far more often than patients expect.
Honest counseling. What the evidence supports, what it does not, and what is legally available. Where an FDA-approved therapy or evidence-supported non-pharmacologic intervention fits, that is what we recommend.
Monitoring. Any therapy we do initiate is followed with scheduled reassessment and repeat labs.
What we don’t yet know
We do not know whether Cerebrolysin changes outcomes patients actually care about. The most rigorous synthesis found no mortality reduction after stroke and a possible increase in non-fatal serious adverse events; the most favorable found a small gain on an examiner-scored scale but none in functional independence.
We do not know how much of the positive literature reflects sponsorship and publication patterns rather than drug effect.
We do not know the product’s composition with the precision expected of a modern drug. It is a biologically derived mixture, not a defined molecule, which makes batch consistency and mechanistic attribution difficult.
We do not know its long-term safety in generally healthy adults using it for cognitive support, because it has not been studied that way. The trials enrolled people with acute stroke, TBI or dementia.
No claim of safety can be made for this compound, and nothing here should be read as evidence that Cerebrolysin treats dementia, Alzheimer’s disease or stroke, or restores lost function. It does not have that standing.
FDA & regulatory status
Cerebrolysin is not approved by the U.S. Food and Drug Administration for any indication. There is no U.S. marketing authorization.
It is a registered prescription medicine in a number of countries in Europe and Asia. Registration abroad is not FDA approval and does not make a product lawful to sell, import or administer here.
Cerebrolysin is also not on the FDA’s 503A Bulks List and was not among the peptide substances FDA referred to its Pharmacy Compounding Advisory Committee in 2026. As a biologically derived mixture rather than a defined peptide, it does not fit that compounding pathway.
FDA’s personal importation policy states that in most circumstances it is illegal for individuals to import unapproved drugs for personal use, with narrow case-by-case enforcement discretion — not a supply channel a medical practice can build treatment around.
Questions we get
Can you prescribe Cerebrolysin at your Orlando office? Cerebrolysin is not FDA-approved and is not available through United States pharmaceutical channels. Dr. St. Marie will go through the evidence and the regulatory position with you directly, and discuss what is actually available for the problem you are trying to solve.
It’s used in dozens of countries — doesn’t that mean it works? Approval standards differ substantially between countries. The independent Cochrane appraisals are notably less favorable than the drug’s regulatory footprint suggests.
Should I order it online? No. Products outside a regulated supply chain carry no assurance of identity, sterility, potency or endotoxin content — and for an injectable derived from animal tissue, those are not academic concerns.
Then what can you do for my brain health? A great deal. Cognitive symptoms in adults are frequently driven by sleep-disordered breathing, insulin resistance, vascular risk, thyroid or hormone changes, medication effects, or untreated mood disorders — all identifiable and modifiable. That is where we start.
Is there any risk in simply trying it? Yes. The Cochrane stroke review found a probable increase in non-fatal serious adverse events alongside no mortality benefit — not a trivial trade.
Related
- 9 — Brain Health & Cognitive Wellness, where nearly every conversation about this compound begins
- 1 — Comprehensive Health Assessment & Foundation, because the evaluation usually finds a more treatable explanation
- 5 — Cardiovascular Health, since vascular risk drives a large share of cognitive decline
- 2 — Inflammation, Disease Risk & Prevention, where post-injury and vascular inflammation belong
Next step
We begin with a comprehensive evaluation and the labs that explain what is actually driving your symptoms. From there, Dr. St. Marie will tell you plainly what the evidence supports and what is not appropriate for you.
Candidacy for any therapy discussed here is determined by Dr. St. Marie through comprehensive evaluation and lab work. It is not appropriate for everyone.
To schedule, call 407-506-4776 or request an appointment online.
Osteopathic Health of Orlando · 4625 Halder Lane, Suite C, Orlando, FL 32814